GlaxoSmithKline plc (the "Company")
Director Shareholding
Further to the announcement made by the Company on 8 November 2017, in respect of the appointment of Dr Hal Barron as Chief Scientific Officer and President, R&D, and Executive Director, Dr Barron assumed his new role on 1 January 2018.
As at the date of his appointment to the Board, Dr Barron held 1,644 American Depositary Shares in the Company.
V A Whyte
Company Secretary
2 January 2018